Effect of CFMTI, an allosteric metabotropic glutamate receptor 1 antagonist with antipsychotic activity, on Fos expression in regions of the brain related to schizophrenia

Neuroscience

Volumn 168, Issue 3, 2010, Pages 787-796

  Suzuki, G ^a   Satow, A ^a   Ohta, H ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

C fos; Clozapine; G protein coupled receptor; Metabotropic glutamate receptor; Negative allosteric modulator; Prefrontal cortex

Indexed keywords

2 CYCLOPROPYL 5 [1 (2 FLUORO 3 PYRIDINYL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL] 2,3 DIHYDRO 1H ISOINDOL 1 ONE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; METABOTROPIC RECEPTOR 1 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; OREXIN; PROTEIN FOS; UNCLASSIFIED DRUG; 2-CYCLOPROPYL-5-(1-(2-FLUORO-3-PYRIDINYL)-5-METHYL-1H-1,2,3-TRIAZOL-4-YL)-2,3-DIHYDRO-1H-ISOINDOL-1-ONE; ISOINDOLE DERIVATIVE; METABOTROPIC RECEPTOR; PROTEIN C FOS; TRIAZOLE DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HYPOTHALAMUS; LOCUS CERULEUS; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SOMATOSENSORY CORTEX; STRIA TERMINALIS; VENTRAL TEGMENTUM; WEIGHT GAIN; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; ISOINDOLES; MALE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; TRIAZOLES;

EID: 77953120623     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.04.016     Document Type: Article

References (46)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 1998, 18:5545-5554.
2. Albanese A., Minciacchi D. Organization of the ascending projections from the ventral tegmental area: a multiple fluorescent retrograde tracer study in the rat. J Comp Neurol 1983, 216:406-420.
3. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001, 62(Suppl 7):22-31.
4. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients. Lancet 1997, 349:1730-1734.
5. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 2000, 31:106-112.
6. Arnsten A.F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004, 174:25-31.
7. Aston-Jones G. Locus coeruleus, A5 and A7 noradrenergic cell groups. The rat nervous systems 2004, 259-294. Elsevier Academic Press, San Diego. G. Paxinos (Ed.).
8. Cassell M.D., Wright D.J. Topography of projections from the medial prefrontal cortex to the amygdala in the rat. Brain Res Bull 1986, 17:321-333.
9. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
10. Conn P.J., Tamminga C., Schoepp D.D., Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol Interv 2008, 8:99-107.
11. Dawe G.S., Huff K.D., Vandergriff J.L., Sharp T., O'Neill M.J., Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 2001, 50:510-520.
12. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 1996, 70:377-389.
13. Fadel J., Bubser M., Deutch A.Y. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002, 22:6742-6746.
14. Ferraguti F., Crepaldi L., Nicoletti F. Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev 2008, 60:536-581.
15. Goudie A.J., Cooper G.D., Halford J.C. Antipsychotic-induced weight gain. Diabetes Obes Metab 2005, 7:478-487.
16. Heimer L., Harlan R.E., Alheid G.F., Garcia M.M., de Olmos J. Substantia innominata: a notion which impedes clinical-anatomical correlations in neuropsychiatric disorders. Neuroscience 1997, 76:957-1006.
17. Herdegen T., Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 1998, 28:370-490.
18. Ito S., Hirata Y., Nagatomi Y., Satoh A., Suzuki G., Kimura T., Satow A., Maehara S., Hikichi H., Hata M., Ohta H., Kawamoto H. Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders. Bioorg Med Chem Lett 2009, 19:5310-5313.
19. Lacroix L., Spinelli S., White W., Feldon J. The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion. Neuroscience 2000, 97:459-468.
20. Langlois M.C., Beaudry G., Zekki H., Rouillard C., Lévesque D. Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience 2001, 106:117-128.
21. Laruelle M., Kegeles L.S., Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 2003, 1003:138-158.
22. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998, 136:153-161.
23. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 1998, 44:1099-1117.
24. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990, 54:1755-1760.
25. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
26. Morgan J.I., Curran T. Stimulus-transcription coupling in neurons: role of cellular immediate-early genes. Trends Neurosci 1989, 12:459-462.
27. Morris B.J., Cochran S.M., Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005, 5:101-106.
28. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003, 28(Suppl 1):83-96.
29. Ohashi K., Hamamura T., Lee Y., Fujiwara Y., Suzuki H., Kuroda S. Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors. Neuropsychopharmacology 2000, 23:162-169.
30. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
31. Paz R.D., Tardito S., Atzori M., Tseng K.Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008, 18:773-786.
32. Perlstein W.M., Dixit N.K., Carter C.S., Noll D.C., Cohen J.D. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry 2003, 53:25-38.
33. Pinna A., Morelli M. Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine. Neuropsychopharmacology 1999, 21:93-100.
34. Pratt J.A., Winchester C., Egerton A., Cochran S.M., Morris B.J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 2008, 153(Suppl 1):S465-S470.
35. Ramirez O.A., Wang R.Y. Locus coeruleus norepinephrine-containing neurons: effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res 1986, 362:165-170.
36. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271:1058-1066.
37. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-Fos expression in rat forebrain. Neuropsychopharmacology 1996, 14:105-110.
38. Satoh A., Nagatomi Y., Hirata Y., Ito S., Suzuki G., Kimura T., Maehara S., Hikichi H., Satow A., Hata M., Ohta H., Kawamoto H. Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorg Med Chem Lett 2009, 19:5464-5468.
39. Satow A., Maehara S., Ise S., Hikichi H., Fukushima M., Suzuki G., Kimura T., Tanak T., Ito S., Kawamoto H., Ohta H. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J Pharmacol Exp Ther 2008, 326:577-586.
40. Satow A., Suzuki G., Maehara S., Hikichi H., Murai T., Murai T., Kawagoe-Takaki H., Hata M., Ito S., Ozaki S., Kawamoto H., Ohta H. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist, CFMTI [2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one]. J Pharmacol Exp Ther 2009, 330:179-190.
41. Sumner B.E., Cruise L.A., Slattery D.A., Hill D.R., Shahid M., Henry B. Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berl) 2004, 171:306-321.
42. Suzuki G., Kimura T., Satow A., Kaneko N., Fukuda J., Hikichi H., Sakai N., Maehara S., Kawagoe-Takaki H., Hata M., Azuma T., Ito S., Kawamoto H., Ohta H. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther 2007, 321:1144-1153.
43. Suzuki G., Kawagoe-Takaki H., Inoue T., Kimura T., Hikichi H., Murai T., Satow A., Hata M., Maehara S., Ito S., Kawamoto H., Ozaki S., Ohta H. Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists. J Pharmacol Sci 2009, 110:315-325.
44. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci 1988, 11:367-370.
45. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 1998, 361:27-33.
46. Ziegler D.R., Cullinan W.E., Herman J.P. Distribution of vesicular glutamate transporter mRNA in rat hypothalamus. J Comp Neurol 2002, 448:217-229.